Kahlon et al. [98] provided proof of concept data showing that first-generation, ligand-based CAR T cells targeting the IL-13Rα2 receptor through the modified IL-13 ligand significantly kill IL-13Rα2-expressing cell lines and prolong progression-free survival in GBM xenograft murine models. This evidence concerns the gene IL13RA2 and glioblastoma.